These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 17051243)

  • 1. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression.
    Balaian L; Zhong RK; Ball ED
    Exp Hematol; 2003 May; 31(5):363-71. PubMed ID: 12763134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
    Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
    ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
    Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML
    Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
    Balaian L; Ball ED
    Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Giles F; Estey E; O'Brien S
    Cancer; 2003 Nov; 98(10):2095-104. PubMed ID: 14601078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
    Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
    Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
    Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
    Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
    Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia.
    Jawad M; Seedhouse C; Mony U; Grundy M; Russell NH; Pallis M
    Leukemia; 2010 Jan; 24(1):74-80. PubMed ID: 19776761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
    Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
    Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
    Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
    Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
    Walter RB; Raden BW; Kamikura DM; Cooper JA; Bernstein ID
    Blood; 2005 Feb; 105(3):1295-302. PubMed ID: 15454492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
    Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
    Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.
    Rutella S; Bonanno G; Procoli A; Mariotti A; Lucia MB; Contemi AM; Cauda R; Fianchi L; Scambia G; Pagano L; Leone G
    Exp Hematol; 2006 Jan; 34(1):54-65. PubMed ID: 16413391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.